查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1941780

腦膜炎雙球菌疫苗市場規模、佔有率和趨勢分析報告：按類型、品牌、血清型、年齡層、銷售管道、地區和細分市場預測，2026-2033年

Meningococcal Vaccines Market Size, Share & Trends Analysis Report By Type, By Brand, By Serotype, By Age Group (Infants ), By Sales Channel, By Region, And Segment Forecasts, 2026 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

腦膜炎雙球菌疫苗市場概述

2025年全球腦膜炎雙球菌疫苗市場規模估計為40.5億美元，預計2033年將達到59.6億美元。

預計2026年至2033年，該市場將以4.5%的複合年成長率成長。腦膜炎發病率的上升預計將是推動市場成長的主要因素之一。

根據美國疾病管制與預防中心（CDC）預測，全球每年約有120萬例細菌性腦膜炎病例。此外，疫苗接種計劃的擴大、公眾對該疾病的認知以及腦膜炎球菌疫苗研發活動的增加，預計將在預測期內推動市場成長。

腦膜炎雙球菌疫苗是預防侵襲性腦膜炎雙球菌病菌感染的重要手段，此病可導致危及生命的腦膜炎和敗血症。這些疫苗有多種配方，包括四價疫苗（MenACWY）、B群疫苗（MenB）和五價疫苗（MenABCWY），分別針對引起疾病的主要血清群（A、B、C、W和Y）。截至2025年，監管機構已擴大核准，涵蓋所有年齡層，MenQuadfi疫苗已獲準用於預防6週齡及以上人群感染A、C、W和Y群腦膜炎球菌。公共衛生部門的常規疫苗接種建議持續強調青少年接種疫苗的重要性，並將其作為疾病控制的基礎。例如，2025年7月，美國疾病管制與預防中心（CDC）的指引重申了青少年和高風險族群常規接種疫苗的重要性。

2024年至2025年的市場和監管趨勢反映出一種策略轉變，即轉向使用能夠簡化免疫接種程序並提高覆蓋率的廣譜保護性疫苗。五價疫苗，例如輝瑞的Pembria和葛蘭素史克的PenMemB（兩者均覆蓋A、B、C、W和Y群腦膜炎球菌），已核准用於10至25歲的人群，並結合了以往需要多種疫苗才能提供的保護。 2025年4月，美國免疫實務諮詢委員會（ACIP）建議，當在同一次臨床就診中同時需要接種MenACWY和MenB疫苗時，應使用五價疫苗，從而簡化接種通訊協定。例如，2025年4月，一個聯邦諮詢委員會建議使用五價腦膜炎雙球菌疫苗，以支持更廣泛、更全面的疫苗接種策略。

公共衛生指導和疫苗接種工作仍然專注於在廣泛保護和有針對性的、基於風險的策略之間取得平衡。 2024年，美國食品藥物管理局（FDA）更新了包括Bexsero在內的B群腦膜炎球菌疫苗的接種方案，以最佳化建議族群的免疫抗原性，這顯示不斷更新的證據和接種方案的持續改進。同時，在低收入地區進行的工作，例如2024年在非洲部分地區引入世界衛生組織建議的五價疫苗，顯示全球需要將腦膜炎雙球菌預防範圍擴大到高所得市場以外的地區。疫苗可近性和政策的持續改進旨在透過適齡免疫接種來減輕全球病菌感染疾病的負擔。

目錄

第1章調查方法和範圍

第2章執行摘要

3. 腦膜炎雙球菌疫苗市場變數、趨勢和範圍

  • 市場體系展望
  • 市場動態
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析

第4章 腦膜炎雙球菌疫苗市場：按類型分類的業務分析

  • 按類型分類的市場佔有率（2025 年和 2033 年）
  • 市場規模、預測與趨勢分析：按類型分類（2021-2033 年）
  • 二價
  • 四價
  • 其他

5. 腦膜炎雙球菌疫苗市場：按品牌分類的業務分析

  • 按品牌分類的市場佔有率（2025 年和 2033 年）
  • 市場規模、預測與趨勢分析：按品牌分類（2021-2033 年）
  • Menactra
  • Menveo
  • Nimenrix
  • Trumenba
  • Bexsero

6. 腦膜炎雙球菌疫苗市場：依血清型分類的業務分析

  • 以血清型分類的市場佔有率（2025 年和 2033 年）
  • 市場規模、預測與趨勢分析：依血清型分類（2021-2033 年）
  • A
  • B
  • C
  • W-135
  • Y

7. 腦膜炎雙球菌疫苗市場：按年齡層別分類的業務分析

  • 按年齡層別分類的市場佔有率（2025 年和 2033 年）
  • 市場規模、預測與趨勢分析：按年齡層別分類（2021-2033 年）
  • 嬰兒（0-2歲）
  • 兒童及成人（2歲以上）

8. 腦膜炎雙球菌疫苗市場：按銷售管道的業務分析

  • 按銷售管道分類的市場佔有率（2025 年和 2033 年）
  • 按銷售管道分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 私人的
  • 民眾

第9章 腦膜炎雙球菌疫苗市場：區域估算與趨勢分析

  • 區域市場佔有率分析（2025 年和 2033 年）
  • 區域市場概覽
  • 市場規模及預測趨勢分析（2021-2033）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第10章 競爭格局

  • 參與公司概況
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/列表
    • GlaxoSmithKline
    • Pfizer
    • Sanofi
    • Merck &Co.
    • Novartis
    • Serum Institute of India
    • Walvax Biotechnology
    • Baxter International
    • Bio-Med Pvt. Ltd.
    • Incepta Vaccine Ltd
Product Code: GVR-4-68039-045-9

Meningococcal Vaccines Market Summary

The global meningococcal vaccines market size was estimated at USD 4.05 billion in 2025 and is projected to reach USD 5.96 billion by 2033, growing at a CAGR of 4.5% from 2026 to 2033. The increasing prevalence of meningitis is one of the major factors expected to drive the market.

According to the Centers for Disease Control and Prevention (CDC), approximately 1.2 million cases of bacterial meningitis are projected worldwide each year. Moreover, expanding immunization programs, greater awareness of the disease, and increased R&D activities for meningococcal vaccines are expected to fuel market growth during the forecast period.

Meningococcal vaccines are critical tools in preventing invasive Neisseria meningitidis infections, which can cause life-threatening meningitis and sepsis. These vaccines target the serogroups most responsible for disease-A, B, C, W, and Y-through distinct formulations, including quadrivalent (MenACWY), serogroup B (MenB), and pentavalent (MenABCWY). As of 2025, regulatory agencies have expanded approvals to improve coverage across age groups, with MenQuadfi licensed for individuals from six weeks of age to provide protection against serogroups A, C, W, and Y. Routine recommendations by public health authorities continue to emphasize adolescent immunization as foundational to disease control. For instance, in July 2025, CDC guidance reinforced the importance of routine vaccination for adolescents and at-risk individuals.

Market and regulatory developments in 2024-2025 reflect a strategic shift toward broader protective vaccines that simplify immunization schedules and enhance uptake. Pentavalent vaccines such as Pfizer's Penbraya and GSK's Penmenvy, each covering serogroups A, B, C, W, and Y, have received approval for use in individuals aged 10-25 years, consolidating protection previously provided by multiple vaccines. In April 2025, ACIP recommended using pentavalent vaccines when both MenACWY and MenB immunizations are indicated during the same clinical visit, streamlining delivery protocols. For instance, in April 2025, a federal advisory committee recommended pentavalent meningococcal vaccines to support broader, integrated vaccination approaches.

Public health guidance and vaccine uptake efforts remain focused on balancing broad protection with targeted risk-based strategies. In 2024, the FDA updated dosing schedules for MenB vaccines, such as Bexsero, to optimize immunogenicity in recommended cohorts, underscoring evolving evidence and refinements to dosing schedules. Concurrently, efforts in lower-income settings, such as the 2024 rollout of WHO-recommended five-strain vaccines in parts of Africa, illustrate the global imperative to extend meningococcal prevention beyond high-income markets. Continuing enhancements in vaccine access and policy aim to reduce the burden of meningococcal disease globally through age-appropriate immunization.

Global Meningococcal Vaccines Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends across sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global meningococcal vaccines market report based on type, brand, serotype, age group, sales channel, and region:

  • Type Outlook (Revenue, USD Million, 2021 - 2033)
  • Bivalent
  • Quadrivalent
  • Others
  • Brand Outlook (Revenue, USD Million, 2021 - 2033)
  • Menactra
  • Menveo
  • Nimenrix
  • Trumenba
  • Bexsero
  • Others
  • Serotype Outlook (Revenue, USD Million, 2021 - 2033)
  • A
  • B
  • C
  • W-135
  • Y
  • Age Group Outlook (Revenue, USD Million, 2021 - 2033)
  • Infants (0 to 2 years)
  • Children and Adults (2 years and above)
  • Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Private
  • Public
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Brand
    • 1.2.3. Serotype
    • 1.2.4. Age Group
    • 1.2.5. Sales Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Meningococcal Vaccines Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Meningococcal Vaccines Market: Type Business Analysis

  • 4.1. Type Market Share, 2025 & 2033
  • 4.2. Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Million)
  • 4.4. Bivalent
    • 4.4.1. Bivalent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5. Quadrivalent
    • 4.5.1. Quadrivalent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Meningococcal Vaccines Market: Brand Business Analysis

  • 5.1. Brand Market Share, 2025 & 2033
  • 5.2. Brand Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Brand, 2021 to 2033 (USD Million)
  • 5.4. Menactra
    • 5.4.1. Menactra Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5. Menveo
    • 5.5.1. Menveo Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6. Nimenrix
    • 5.6.1. Nimenrix Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7. Trumenba
    • 5.7.1. Trumenba Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.8. Bexsero
    • 5.8.1. Bexsero Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Meningococcal Vaccines Market: Serotype Business Analysis

  • 6.1. Serotype Market Share, 2025 & 2033
  • 6.2. Serotype Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Serotype, 2021 to 2033 (USD Million)
  • 6.4. A
    • 6.4.1. A Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.5. B
    • 6.5.1. B Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.6. C
    • 6.6.1. C Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.7. W-135
    • 6.7.1. W-135 Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 6.8. Y
    • 6.8.1. Y Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 7. Meningococcal Vaccines Market: Age Group Business Analysis

  • 7.1. Age Group Market Share, 2025 & 2033
  • 7.2. Age Group Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Age Group, 2021 to 2033 (USD Million)
  • 7.4. Infants (0 to 2 years)
    • 7.4.1. Infants (0 to 2 years) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 7.5. Children and Adults (2 years and above)
    • 7.5.1. Children and Adults (2 years and above) Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 8. Meningococcal Vaccines Market: Sales Channel Business Analysis

  • 8.1. Sales Channel Market Share, 2025 & 2033
  • 8.2. Sales Channel Segment Dashboard
  • 8.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
  • 8.4. Private
    • 8.4.1. Private Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 8.5. Public
    • 8.5.1. Public Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 9. Meningococcal Vaccines Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Market Share Analysis, 2025 & 2033
  • 9.2. Regional Market Dashboard
  • 9.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 9.4. North America
    • 9.4.1. North America Meningococcal Vaccines Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
    • 9.4.2. U.S.
      • 9.4.2.1. Key Country Dynamics
      • 9.4.2.2. Type Disease Prevalence
      • 9.4.2.3. Regulatory Framework
      • 9.4.2.4. Reimbursement Framework
      • 9.4.2.5. U.S. Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.3. Canada
      • 9.4.3.1. Key Country Dynamics
      • 9.4.3.2. Type Disease Prevalence
      • 9.4.3.3. Regulatory Framework
      • 9.4.3.4. Reimbursement Framework
      • 9.4.3.5. Canada Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.4.4. Mexico
      • 9.4.4.1. Key Country Dynamics
      • 9.4.4.2. Type Disease Prevalence
      • 9.4.4.3. Regulatory Framework
      • 9.4.4.4. Reimbursement Framework
      • 9.4.4.5. Mexico Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.5. Europe
    • 9.5.1. Europe Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.2. UK
      • 9.5.2.1. Key Country Dynamics
      • 9.5.2.2. Type Disease Prevalence
      • 9.5.2.3. Regulatory Framework
      • 9.5.2.4. Reimbursement Framework
      • 9.5.2.5. UK Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.3. Germany
      • 9.5.3.1. Key Country Dynamics
      • 9.5.3.2. Type Disease Prevalence
      • 9.5.3.3. Regulatory Framework
      • 9.5.3.4. Reimbursement Framework
      • 9.5.3.5. Germany Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.4. France
      • 9.5.4.1. Key Country Dynamics
      • 9.5.4.2. Type Disease Prevalence
      • 9.5.4.3. Regulatory Framework
      • 9.5.4.4. Reimbursement Framework
      • 9.5.4.5. France Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.5. Italy
      • 9.5.5.1. Key Country Dynamics
      • 9.5.5.2. Type Disease Prevalence
      • 9.5.5.3. Regulatory Framework
      • 9.5.5.4. Reimbursement Framework
      • 9.5.5.5. Italy Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.6. Spain
      • 9.5.6.1. Key Country Dynamics
      • 9.5.6.2. Type Disease Prevalence
      • 9.5.6.3. Regulatory Framework
      • 9.5.6.4. Reimbursement Framework
      • 9.5.6.5. Spain Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.7. Denmark
      • 9.5.7.1. Key Country Dynamics
      • 9.5.7.2. Type Disease Prevalence
      • 9.5.7.3. Regulatory Framework
      • 9.5.7.4. Reimbursement Framework
      • 9.5.7.5. Denmark Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.8. Sweden
      • 9.5.8.1. Key Country Dynamics
      • 9.5.8.2. Type Disease Prevalence
      • 9.5.8.3. Regulatory Framework
      • 9.5.8.4. Reimbursement Framework
      • 9.5.8.5. Sweden Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.5.9. Norway
      • 9.5.9.1. Key Country Dynamics
      • 9.5.9.2. Type Disease Prevalence
      • 9.5.9.3. Regulatory Framework
      • 9.5.9.4. Reimbursement Framework
      • 9.5.9.5. Norway Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.6. Asia Pacific
    • 9.6.1. Asia Pacific Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.2. Japan
      • 9.6.2.1. Key Country Dynamics
      • 9.6.2.2. Type Disease Prevalence
      • 9.6.2.3. Regulatory Framework
      • 9.6.2.4. Reimbursement Framework
      • 9.6.2.5. Japan Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.3. China
      • 9.6.3.1. Key Country Dynamics
      • 9.6.3.2. Type Disease Prevalence
      • 9.6.3.3. Regulatory Framework
      • 9.6.3.4. Reimbursement Framework
      • 9.6.3.5. China Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.4. India
      • 9.6.4.1. Key Country Dynamics
      • 9.6.4.2. Type Disease Prevalence
      • 9.6.4.3. Regulatory Framework
      • 9.6.4.4. Reimbursement Framework
      • 9.6.4.5. India Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.5. Australia
      • 9.6.5.1. Key Country Dynamics
      • 9.6.5.2. Type Disease Prevalence
      • 9.6.5.3. Regulatory Framework
      • 9.6.5.4. Reimbursement Framework
      • 9.6.5.5. Australia Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.6. South Korea
      • 9.6.6.1. Key Country Dynamics
      • 9.6.6.2. Type Disease Prevalence
      • 9.6.6.3. Regulatory Framework
      • 9.6.6.4. Reimbursement Framework
      • 9.6.6.5. South Korea Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.6.7. Thailand
      • 9.6.7.1. Key Country Dynamics
      • 9.6.7.2. Type Disease Prevalence
      • 9.6.7.3. Regulatory Framework
      • 9.6.7.4. Reimbursement Framework
      • 9.6.7.5. Thailand Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.7. Latin America
    • 9.7.1. Latin America Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.2. Brazil
      • 9.7.2.1. Key Country Dynamics
      • 9.7.2.2. Type Disease Prevalence
      • 9.7.2.3. Regulatory Framework
      • 9.7.2.4. Reimbursement Framework
      • 9.7.2.5. Brazil Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.7.3. Argentina
      • 9.7.3.1. Key Country Dynamics
      • 9.7.3.2. Type Disease Prevalence
      • 9.7.3.3. Regulatory Framework
      • 9.7.3.4. Reimbursement Framework
      • 9.7.3.5. Argentina Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 9.8. Middle East and Africa
    • 9.8.1. Middle East and Africa Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.2. South Africa
      • 9.8.2.1. Key Country Dynamics
      • 9.8.2.2. Type Disease Prevalence
      • 9.8.2.3. Regulatory Framework
      • 9.8.2.4. Reimbursement Framework
      • 9.8.2.5. South Africa Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.3. Saudi Arabia
      • 9.8.3.1. Key Country Dynamics
      • 9.8.3.2. Type Disease Prevalence
      • 9.8.3.3. Regulatory Framework
      • 9.8.3.4. Reimbursement Framework
      • 9.8.3.5. Saudi Arabia Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.4. UAE
      • 9.8.4.1. Key Country Dynamics
      • 9.8.4.2. Type Disease Prevalence
      • 9.8.4.3. Regulatory Framework
      • 9.8.4.4. Reimbursement Framework
      • 9.8.4.5. UAE Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 9.8.5. Kuwait
      • 9.8.5.1. Key Country Dynamics
      • 9.8.5.2. Type Disease Prevalence
      • 9.8.5.3. Regulatory Framework
      • 9.8.5.4. Reimbursement Framework
      • 9.8.5.5. Kuwait Meningococcal Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Participant Overview
  • 10.2. Company Market Position Analysis
  • 10.3. Company Categorization
  • 10.4. Strategy Mapping
  • 10.5. Company Profiles/Listing
    • 10.5.1. GlaxoSmithKline
      • 10.5.1.1. Overview
      • 10.5.1.2. Financial Performance
      • 10.5.1.3. Type Benchmarking
      • 10.5.1.4. Strategic Initiatives
    • 10.5.2. Pfizer
      • 10.5.2.1. Overview
      • 10.5.2.2. Financial Performance
      • 10.5.2.3. Type Benchmarking
      • 10.5.2.4. Strategic Initiatives
    • 10.5.3. Sanofi
      • 10.5.3.1. Overview
      • 10.5.3.2. Financial Performance
      • 10.5.3.3. Type Benchmarking
      • 10.5.3.4. Strategic Initiatives
    • 10.5.4. Merck & Co.
      • 10.5.4.1. Overview
      • 10.5.4.2. Financial Performance
      • 10.5.4.3. Type Benchmarking
      • 10.5.4.4. Strategic Initiatives
    • 10.5.5. Novartis
      • 10.5.5.1. Overview
      • 10.5.5.2. Financial Performance
      • 10.5.5.3. Type Benchmarking
      • 10.5.5.4. Strategic Initiatives
    • 10.5.6. Serum Institute of India
      • 10.5.6.1. Overview
      • 10.5.6.2. Financial Performance
      • 10.5.6.3. Type Benchmarking
      • 10.5.6.4. Strategic Initiatives
    • 10.5.7. Walvax Biotechnology
      • 10.5.7.1. Overview
      • 10.5.7.2. Financial Performance
      • 10.5.7.3. Type Benchmarking
      • 10.5.7.4. Strategic Initiatives
    • 10.5.8. Baxter International
      • 10.5.8.1. Overview
      • 10.5.8.2. Financial Performance
      • 10.5.8.3. Type Benchmarking
      • 10.5.8.4. Strategic Initiatives
    • 10.5.9. Bio-Med Pvt. Ltd.
      • 10.5.9.1. Overview
      • 10.5.9.2. Financial Performance
      • 10.5.9.3. Type Benchmarking
      • 10.5.9.4. Strategic Initiatives
    • 10.5.10. Incepta Vaccine Ltd
      • 10.5.10.1. Overview
      • 10.5.10.2. Financial Performance
      • 10.5.10.3. Type Benchmarking
      • 10.5.10.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Meningococcal Vaccines Market, by Region, 2021 - 2033 (USD Million)
  • Table 4 Global Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 5 Global Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 6 Global Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 7 Global Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 8 Global Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 9 North America Meningococcal Vaccines Market, by Country, 2021 - 2033 (USD Million)
  • Table 10 North America Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 11 North America Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 12 North America Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 13 North America Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 14 North America Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 15 U.S Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 16 U.S Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 17 U.S Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 18 U.S Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 19 U.S Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 20 Canada Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 21 Canada Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 22 Canada Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 23 Canada Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 24 Canada Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 25 Mexico Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 26 Mexico Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 27 Mexico Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 28 Mexico Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 29 Mexico Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 30 Europe Meningococcal Vaccines Market, by Country, 2021 - 2033 (USD Million)
  • Table 31 Europe Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 32 Europe Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 33 Europe Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 34 Europe Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 35 Europe Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 36 UK Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 37 UK Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 38 UK Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 39 UK Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 40 UK Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 41 Germany Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 42 Germany Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 43 Germany Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 44 Germany Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 45 Germany Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 46 France Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 47 France Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 48 France Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 49 France Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 50 France Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 51 Italy Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 52 Italy Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 53 Italy Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 54 Italy Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 55 Italy Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 56 Spain Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 57 Spain Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 58 Spain Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 59 Spain Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 60 Spain Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 61 Denmark Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 62 Denmark Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 63 Denmark Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 64 Denmark Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 65 Denmark Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 66 Norway Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 67 Norway Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 68 Norway Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 69 Norway Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 70 Norway Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 71 Sweden Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 72 Sweden Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 73 Sweden Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 74 Sweden Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 75 Sweden Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 76 Asia Pacific Meningococcal Vaccines Market, by Country, 2021 - 2033 (USD Million)
  • Table 77 Asia Pacific Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 78 Asia Pacific Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 79 Asia Pacific Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 80 Asia Pacific Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 81 Asia Pacific Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 82 Japan Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 83 Japan Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 84 Japan Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 85 Japan Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 86 Japan Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 87 China Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 88 China Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 89 China Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 90 China Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 91 China Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 92 India Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 93 India Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 94 India Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 95 India Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 96 India Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 97 South Korea Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 98 South Korea Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 99 South Korea Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 100 South Korea Meningococcal Vaccines Market, by Route of Administration, 2021 - 2033 (USD Million)
  • Table 101 South Korea Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 102 Australia Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 103 Australia Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 104 Australia Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 105 Australia Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 106 Australia Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 107 Thailand Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 108 Thailand Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 109 Thailand Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 110 Thailand Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 111 Thailand Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 112 Latin America Meningococcal Vaccines Market, by Country, 2021 - 2033 (USD Million)
  • Table 113 Latin America Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 114 Latin America Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 115 Latin America Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 116 Latin America Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 117 Latin America Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 118 Brazil Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 119 Brazil Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 120 Brazil Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 121 Brazil Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 122 Brazil Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 123 Argentina Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 124 Argentina Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 125 Argentina Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 126 Argentina Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 127 Argentina Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 128 Middle East & Africa Meningococcal Vaccines Market, by Country, 2021 - 2033 (USD Million)
  • Table 129 Middle East & Africa Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 130 Middle East & Africa Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 131 Middle East & Africa Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 132 Middle East & Africa Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 133 Middle East & Africa Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 134 South Africa Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 135 South Africa Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 136 South Africa Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 137 South Africa Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 138 South Africa Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 139 Saudi Arabia Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 140 Saudi Arabia Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 141 Saudi Arabia Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 142 Saudi Arabia Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 143 Saudi Arabia Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 144 UAE Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 145 UAE Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 146 UAE Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 147 UAE Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 148 UAE Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)
  • Table 149 Kuwait Meningococcal Vaccines Market, by Type, 2021 - 2033 (USD Million)
  • Table 150 Kuwait Meningococcal Vaccines Market, by Brand, 2021 - 2033 (USD Million)
  • Table 151 Kuwait Meningococcal Vaccines Market, by Serotype, 2021 - 2033 (USD Million)
  • Table 152 Kuwait Meningococcal Vaccines Market, by Age Group, 2021 - 2033 (USD Million)
  • Table 153 Kuwait Meningococcal Vaccines Market, by Sales Channel, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Meningococcal Vaccines market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease outlook (USD Million)
  • Fig. 10 Competitive landscape
  • Fig. 11 Meningococcal Vaccines market dynamics
  • Fig. 12 Meningococcal Vaccines market: Porter's five forces analysis
  • Fig. 13 Meningococcal Vaccines market: PESTLE analysis
  • Fig. 14 Type market, 2021 - 2033 (USD Million)
  • Fig. 15 Bivalent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 16 Quadrivalent Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 17 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 Brand market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 Menactra market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 Menveo market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Nimenrix market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Trumenba market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Bexsero market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Others market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Serotype market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 A market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 B market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 C market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 W-135 Molecule market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Y market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Age Group market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Infants (0 to 2 years) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Children and Adults (2 years and above) market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Sales Channel market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Private market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Public market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Meningococcal Vaccines market revenue, by region
  • Fig. 38 Regional marketplace: Key takeaways
  • Fig. 39 North America meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 U.S country dynamics
  • Fig. 41 U.S meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Canada country dynamics
  • Fig. 43 Canada meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 Mexico country dynamics
  • Fig. 45 Mexico meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 Europe meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 UK country dynamics
  • Fig. 48 UK meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 Germany country dynamics
  • Fig. 50 Germany meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 France country dynamics
  • Fig. 52 France meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 Italy country dynamics
  • Fig. 54 Italy meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 Spain country dynamics
  • Fig. 56 Spain meningococcal vaccines market, 2021 - 2033 (USD Million)
  • Fig. 57 Norway country dynamics
  • Fig. 58 Norway meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Sweden country dynamics
  • Fig. 60 Sweden meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 Denmark country dynamics
  • Fig. 62 Denmark meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Asia Pacific meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 Japan country dynamics
  • Fig. 65 Japan meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 China country dynamics
  • Fig. 67 China meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 India country dynamics
  • Fig. 69 India meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 Australia country dynamics
  • Fig. 71 Australia meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 South Korea country dynamics
  • Fig. 73 South Korea meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Thailand country dynamics
  • Fig. 75 Thailand meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 Latin America meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 77 Brazil country dynamics
  • Fig. 78 Brazil meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Argentina country dynamics
  • Fig. 80 Argentina meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 MEA meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 South Africa country dynamics
  • Fig. 83 South Africa meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 Saudi Arabia country dynamics
  • Fig. 85 Saudi Arabia meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 UAE country dynamics
  • Fig. 87 UAE meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Kuwait country dynamics
  • Fig. 89 Kuwait meningococcal vaccines market estimates and forecasts, 2021 - 2033 (USD Million)
  • Fig. 90 Company categorization
  • Fig. 91 Company market position analysis
  • Fig. 92 Strategic framework